Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
OncoHost is a commercial-stage precision oncology company revolutionizing the approach to cancer treatment. Their core offering, the PROphet® platform, utilizes advanced AI and machine learning algorithms to analyze changes in blood-based proteomic profiles. This enables oncologists to predict patient response to specific cancer therapies, primarily immunotherapies, helping to personalize treatment strategies, improve patient outcomes, and reduce ineffective treatments. OncoHost aims to provide actionable, real-time insights to guide clinical decision-making in oncology.
Serves as the central hub for research and development of its AI-powered precision oncology platform, PROphet®, as well as global strategic management, corporate operations, and bioinformatics.
Modern laboratory and office facilities situated within the Binyamina Industrial Zone, equipped for advanced proteomic analysis, AI model development, and computational research.
Characterized by a highly innovative, collaborative, and research-intensive environment. It brings together experts in oncology, data science, AI, and molecular biology, all focused on a patient-centric mission to transform cancer care.
Strategically located in Israel, a global center for technological and biomedical innovation, enabling access to top-tier talent and a supportive ecosystem for growth in the precision medicine field. It's the nerve center for OncoHost's pioneering work.
OncoHost operates with a global outlook, with its primary R&D and corporate functions headquartered in Israel and significant laboratory and commercial operations in the United States (Research Triangle Park, NC). The company collaborates internationally with leading academic institutions, hospitals, and pharmaceutical partners on clinical trials and research initiatives to validate and expand the applications of its PROphet® platform worldwide. Their services and technology are designed for global applicability in oncology.
7 Hanagar St, Binyamina Industrial Park
Binyamina
Haifa District
Israel
Address: 7020 Kit Creek Rd, Suite 250, Research Triangle Park, NC 27709, USA
Serves as OncoHost's operational hub in North America, facilitating engagement with the U.S. healthcare system, supporting clinical studies, fostering collaborations with U.S. research institutions and pharmaceutical companies, and spearheading commercial activities in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, OncoHost' leadership includes:
OncoHost has been backed by several prominent investors over the years, including:
In the past 12 months, OncoHost has strengthened its executive team with key appointments in finance and commercial operations, reflecting its growth and focus on market expansion. No major executive departures have been publicly announced during this period.
Discover the tools OncoHost uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
OncoHost likely utilizes common professional email formats. Based on typical company structures of its size and industry, the most probable format is a combination of the employee's first initial and last name, or first name and last name separated by a dot.
Common formats include [first_initial][last]@oncohost.com (e.g., jsmith@oncohost.com) or [first].[last]@oncohost.com (e.g., john.smith@oncohost.com).
Format
osharon@oncohost.com
Example
90%
Success rate
Business Wire • June 3, 2024
OncoHost shared promising new data at the American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the PROphet® platform's capability to predict clinical outcomes and inform treatment decisions for non-small cell lung cancer (NSCLC) patients undergoing immunotherapy....more
OncoHost News • May 21, 2024
OncoHost announced the enrollment of the first patient in its 'PreRectal' clinical study. This prospective trial aims to evaluate the PROphet® platform's ability to predict response to neoadjuvant therapy in patients with locally advanced rectal cancer (LARC)....more
Business Wire • April 9, 2024
OncoHost secured a U.S. patent for its innovative AI-driven blood test technology designed to predict patient responsiveness to immunotherapy, further solidifying its intellectual property portfolio in precision oncology....more
GlobeNewswire • February 20, 2024
A study published in the Journal for ImmunoTherapy of Cancer (JITC) validated the PROphet® platform's ability to predict melanoma patients' response to immunotherapy using pre-treatment blood samples, marking a significant step in personalized melanoma care....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including OncoHost, are just a search away.